Prodarsan® Granted Orphan Drug Designation From FDA
Biotech company Pharming Group NV (“Pharming†or “the Companyâ€) (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage BV (“DNageâ€) has received a notice from the US Food and Drug Administration (“FDAâ€) that its product Prodarsan® has been awarded an Orphan Drug designation for the treatment of Cockayne Syndrome. Prodarsan® is a combination of two small… Read More »